Design and analysis of post-marketing research

被引:3
|
作者
Zhou, Xiao-Hua [1 ,2 ,3 ]
Wei, Yang [4 ]
机构
[1] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA
[2] Renmin Univ China, Sch Stat, Beijing 100872, Peoples R China
[3] VA Seattle Med Ctr, Biostat Unit, Seattle, WA USA
[4] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China
关键词
traditional Chinese medicine post-marketing research; safety surveillance; pharmacovigilance methods; propensity score; ADJUSTMENT;
D O I
10.1007/s11655-013-1501-z
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
A post-marketing study is an integral part of research that helps to ensure a favorable risk-benefit profile for approved drugs used in the market. Because most of post-marketing studies use observational designs, which are liable to confounding, estimation of the causal effect of a drug versus a comparative one is very challenging. This article focuses on methodological issues of importance in designing and analyzing studies to evaluate the safety of marketed drugs, especially marketed traditional Chinese medicine (TCM) products. Advantages and limitations of the current designs and analytic methods for postmarketing studies are discussed, and recommendations are given for improving the validity of postmarketing studies in TCM products.
引用
收藏
页码:488 / 493
页数:6
相关论文
共 50 条
  • [1] Design and Analysis of Post-marketing Research
    周晓华
    杨伟
    Chinese Journal of Integrative Medicine, 2013, (07) : 488 - 493
  • [2] Design and Analysis of Post-marketing Research
    周晓华
    杨伟
    Chinese Journal of Integrative Medicine, 2013, 19 (07) : 488 - 493
  • [3] Design and analysis of post-marketing research
    Xiao-Hua Andrew Zhou
    Wei Yang
    Chinese Journal of Integrative Medicine, 2013, 19 : 488 - 493
  • [4] POST-MARKETING SAFETY STUDIES Three design aspects for high quality post-marketing cohort studies
    Fralick, Michael
    Kesselheim, Aaron S.
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [5] Developments in post-marketing comparative effectiveness research
    Schneeweiss, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (02) : 143 - 156
  • [6] POST-MARKETING SURVEILLANCE
    ROBSON, RH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (03) : 404 - 404
  • [7] Ibrutinib: A post-marketing safety analysis.
    Elias, Rawad
    Pudusseri, Anita
    Akinboro, Oladimeji
    White, Paul S.
    Sarosiek, Shayna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] POST-MARKETING SURVEILLANCE
    SULLMAN, SF
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1979, 72 (01) : 65 - 66
  • [9] A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab
    Li, Huqun
    Wang, Chongshu
    Guo, Cuilian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2025, 13 (03):
  • [10] POST-MARKETING SURVEILLANCE
    CULLITON, BJ
    WATERFALL, WK
    BRITISH MEDICAL JOURNAL, 1980, 280 (6224): : 1175 - 1176